# Accel Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accel-diagnostics

- Industry: Healthcare
- Headquarters: Pittsburgh, US
- Website: www.acceldx.com
- Latest round: Seed (Apr 25, 2013)
- Investors on record: 1

## About

Accel Diagnostics provides innovative laboratory testing services, specializing in COVID-19 diagnostics, drug testing, and health panels to deliver rapid and accurate health information for individuals and businesses.Accel Diagnostics, established in 2008 and headquartered in Pittsburgh, US, operates as a diagnostic laboratory focusing on a range of laboratory testing services. The company was founded by Alberto Gandini, who has experience in the healthcare sector. In May 2016, Accel Diagnostics raised USD 0.65 mn in a Seed funding round, bringing the total amount raised to USD 0.65 mn across 6 deals.ADX Diagnostic Lab specializes in providing a range of laboratory testing services designed to meet the needs of both individuals and businesses. Their core offerings include COVID-19 testing options (RT-PCR, Antigen, and Antibody tests), drug testing panels (5, 10, and 14 panel tests), and various health panels targeting specific health concerns such as diabetes, thyroid function, and sexually transmitted diseases (STDs). These services enable clients to swiftly obtain accurate health information without the inconvenience of long waiting times often associated with traditional medical testing facilities. ADX caters to a diverse clientele, including uninsured individuals, those with high deductibles, and employers seeking drug testing solutions for their workforce. The laboratory operates primarily in the Houston, Texas area but is equipped to serve clients across various geographical markets that require rapid and reliable testing solutions.Revenue generation at ADX Diagnostic Lab is primarily derived from direct transactions involving individual consumers and corporate clients seeking testing services. Customers can book appointments online or walk in for testing, with payments processed either at the time of testing or in advance through their website. Pricing for individual tests is straightforward, with specific costs outlined for various panels and services, such as the Women’s Health Panel and Complete Blood Count, ensuring transparency for clients. The business model facilitates both direct-to-consumer engagement and B2B partnerships, particularly in providing drug testing services to employers in compliance with regulatory requirements. Each transaction is structured around the specific testing services utilized, ensuring that clients receive timely and accurate results tailored to their healthcare needs.Accel Diagnostics plans to leverage its recent funding from May 2016 to enhance its product offerings and expand its market reach. Upcoming products include advanced testing solutions that cater to emerging health concerns, with scheduled launches expected within the next year. Additionally, the company aims to enter new geographic markets, particularly focusing on the southeastern US by the end of 2024, to provide its extensive testing services to a broader audience.

## Funding rounds

- Seed, Apr 25, 2013 — Sinovation Ventures

## Investors

- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Seed